We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-2.04%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$714M
AUM Growth
+$37.8M
Cap. Flow
+$141M
Cap. Flow %
19.78%
Top 10 Hldgs %
80.08%
Holding
30
New
8
Increased
5
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$55.1M
2
AAPL icon
Apple
AAPL
+$52.2M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$50M
4
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$6.17M
5
FOLD
Amicus Therapeutics
FOLD
+$5.71M

Top Sells

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$21.9M
2
KIDS icon
OrthoPediatrics
KIDS
+$19.9M
3
XLRN
Acceleron Pharma
XLRN
+$3.25M
4
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$3.08M
5
DERM
Dermira, Inc.
DERM
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 79.61%
2 Technology 7.43%
3 Communication Services 7.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$167M
$237M 33.2%
3,549,321
+1
+0% +$76
MIST icon
2
Milestone Pharmaceuticals
MIST
$144M
$72.6M 10.17%
+2,674,470
New +$55.1M
AAPL icon
3
Apple
AAPL
$4.89T
$53M 7.43%
+1,071,152
New +$52.2M
CABO icon
4
Cable One
CABO
$213M
$52.7M 7.38%
45,000
– –
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$52.4M 7.35%
+2,645,446
New +$50M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$28.9M 4.05%
2,317,870
+450,000
+24% +$5.71M
GKOS icon
7
Glaukos
GKOS
$9.02B
$22.6M 3.17%
300,000
-305,266
-50% -$21.9M
SIBN icon
8
SI-BONE Inc
SIBN
$737M
$18.2M 2.54%
892,684
-1
-0% -$17
SPNE
9
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$17.3M 2.43%
1,308,037
– –
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
$16.8M 2.36%
570,036
+119,322
+26% +$4.6M
CRVS icon
11
Corvus Pharmaceuticals
CRVS
$1.1B
$16.5M 2.32%
4,420,516
– –
AKBA icon
12
Akebia Therapeutics
AKBA
$327M
$15M 2.1%
3,100,000
– –
ETTX
13
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$14.1M 1.97%
2,181,843
– –
LKFT
14
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$12.6M 1.76%
97,481
– –
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$12.5M 1.76%
132,976
+65,409
+97% +$5.4M
INSP icon
16
Inspire Medical Systems
INSP
$1.42B
$10.6M 1.49%
175,000
– –
NBRV
17
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$8.38M 1.17%
13,786
-5,029
-27% -$3.08M
STIM icon
18
Neuronetics
STIM
$120M
$7.29M 1.02%
582,798
+57,798
+11% +$817K
MRUS
19
DELISTED
Merus
MRUS
$7.25M 1.02%
495,016
-7,779
-2% -$111K
SILK
20
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.03M 0.98%
+145,000
New +$6.17M
KIDS icon
21
OrthoPediatrics
KIDS
$485M
$6.27M 0.88%
160,742
-493,807
-75% -$19.9M
SPRO icon
22
Spero Therapeutics
SPRO
$68.9M
$5.36M 0.75%
+465,983
New +$5.61M
XLRN
23
DELISTED
Acceleron Pharma
XLRN
$4.92M 0.69%
119,708
-78,553
-40% -$3.25M
VRNA
24
DELISTED
Verona Pharma
VRNA
$3.78M 0.53%
740,740
– –
CRNX icon
25
Crinetics Pharmaceuticals
CRNX
$8.86B
$3.38M 0.47%
135,009
– –
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q2 2019 Portfolio in Review

As of Q2 2019, Novo Holdings A/S held 30 positions worth $714M, up 5.6% from $676M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Novo Holdings A/S deployed $141M of net new capital in Q2 2019, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 2,674,470 shares worth $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 87% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Glaukos, an estimated $21.9M trimmed.

  • Novo Holdings A/S's largest Q2 2019 buy was Milestone Pharmaceuticals: 2,674,470 shares worth $72.6M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q2 2019, an estimated $5.71M increase.
  • Novo Holdings A/S's biggest Q2 2019 reduction was Glaukos, cutting an estimated $21.9M.
  • Novo Holdings A/S fully exited Dermira, Inc. in Q2 2019, selling an estimated $2.72M.
  • Novo Holdings A/S's ten largest holdings make up 80% of its $714M portfolio in Q2 2019.
  • Novo Holdings A/S opened 8 new positions and closed 1 in Q2 2019.
  • Novo Holdings A/S's portfolio value rose 5.6% quarter-over-quarter to $714M.

Based on Novo Holdings A/S's 13F filing for Q2 2019, filed 14 Aug 2019.